Early administration of the drug in this analysis resulted in a 28% reduction in the relative risk of death as compared with the administration of the drug in the hemodynamics room 4.7% x 3.4%, although this was not statistically significant.
4. El uso precoz del fármaco, en ese análisis, resultó en una reducción del 28% en el riesgo relativo de muerte en relación al uso en sala de hemodinámica 4,7% vs 3,4%, aunque sin significancia estadística.
Tais achados também foram confirmados pelo recente estudo RELax AMI.